Arcapta Neohaler Approved for COPD

ARCAPTA NEOHALER (indacaterol) 75mcg inhalation powder by Novartis
ARCAPTA NEOHALER (indacaterol) 75mcg inhalation powder by Novartis

Novartis announced FDA approval of Arcapta Neohaler (indacaterol inhalation powder) for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Arcapta Neohaler demonstrated improvements in lung function and also is approved with data demonstrating improvement in health-related quality of life.

Arcapta Neohaler is a long acting beta2-agonist for maintenance treatment of airflow obstruction in patients with COPD.

For more information call (888) NOW-NOVA or visit www.pharma.us.novartis.com/info/products.